Altogether, these results show that the continuous delivery of bsAb CD33–CD3, together with a constant stimulation of T cells by modified MSCs, improves specific killing of autologous AML blasts and increases patient-derived T-cell proliferation over time. This evidence concerns the gene CD33 and acute myeloid leukemia.